Current Landscape of Hepcidin Therapeutics
Advances in Experimental Medicine and Biology · 2025 · 399-418
DOI: 10.1007/978-3-031-92033-2_26 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advances in Experimental Medicine and Biology, online erschienen am 03.07.2025. Verfasst von Antonella Nai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Regulation of Iron Metabolism Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy. Hauptthemen laut MEDLINE: Hepcidins, Iron, Anemia, Iron-Deficiency. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 119 Literaturangaben.
Abstract (Originalsprache)
Hepcidin, the master regulator of systemic iron homeostasis, modulates the absorption of dietary iron as well as its release from stores by blocking and inducing the degradation of ferroportin, the only known cellular iron exporter. Thus, the interaction between hepcidin and ferroportin negatively regulates iron transport into plasma and reduces systemic iron availability. Several genetic and acquired iron-related disorders are characterized by dysregulated hepcidin expression. While hereditary hemochromatosis and β-thalassemia exhibit hepcidin suppression, causing iron overload, iron-refractory iron-deficiency anemia and anemia of chronic diseases show hepcidin induction, promoting iron deficiency. In the last decade, experimental evidence demonstrated that targeting the hepcidin-ferroportin axis and restoring normal hepcidin levels offer potential therapeutic benefits to patients with iron-related disorders. Due to these reasons, the development of hepcidin therapeutics has been exponentially growing in recent years, with the aim to design hepcidin modulators that either mimic or inhibit hepcidin action, leading to reduced or increased iron availability, respectively. This chapter summarizes the current landscape of hepcidin therapeutics that reached clinical development and the pathologies that could benefit from these pharmacological approaches. Moreover, it provides novel experimental insights into new potential therapies combining hepcidin modulators with existing or novel approaches such as luspatercept or TfR2 targeting as a way to achieve further improvement of anemia in pathologic conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regulation of Iron Metabolism Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy.
- Vita-Salute San Raffaele University, Milan, Italy.
- Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
- Iron Research Laboratory, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.
- Iron Research Laboratory, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA. FVinchi@nybc.org.
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA. FVinchi@nybc.org.
Zitieren
APA
Nai, A., Silvestri, L., Asperti, M., & Vinchi, F. (2025). Current Landscape of Hepcidin Therapeutics. Advances in Experimental Medicine and Biology, 399-418. https://doi.org/10.1007/978-3-031-92033-2_26
Vancouver
Nai A, Silvestri L, Asperti M, Vinchi F. Current Landscape of Hepcidin Therapeutics. Advances in Experimental Medicine and Biology. 2025:399-418. doi:10.1007/978-3-031-92033-2_26
BibTeX
@article{Nai2025,
author = {Nai, Antonella and Silvestri, Laura and Asperti, Michela and Vinchi, Francesca},
title = {Current Landscape of Hepcidin Therapeutics},
journal = {Advances in Experimental Medicine and Biology},
year = {2025},
pages = {399--418},
doi = {10.1007/978-3-031-92033-2_26}
}
EUVIMED